| 7.33 -0.22 (-2.91%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.19 |
1-year : | 10.74 |
| Resists | First : | 7.87 |
Second : | 9.19 |
| Pivot price | 6.82 |
|||
| Supports | First : | 6.9 |
Second : | 6.3 |
| MAs | MA(5) : | 7.31 |
MA(20) : | 6.79 |
| MA(100) : | 6.62 |
MA(250) : | 6.3 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 87.3 |
D(3) : | 90.8 |
| RSI | RSI(14): 64.1 |
|||
| 52-week | High : | 8.94 | Low : | 3.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PROF ] has closed below upper band by 13.6%. Bollinger Bands are 9.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.58 - 7.61 | 7.61 - 7.63 |
| Low: | 7.2 - 7.22 | 7.22 - 7.26 |
| Close: | 7.5 - 7.54 | 7.54 - 7.59 |
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Tue, 07 Jul 2026
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last? - Yahoo Finance
Sun, 05 Jul 2026
Profound Medical Corp. (PROF) Edges Higher as Support Holds Near $6.50 - Put Dominated - dars.gov.et
Fri, 26 Jun 2026
PROF Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 25 Jun 2026
Profound Medical Corp Actuals & Estimates (NASDAQ:PROF) - TradingView
Mon, 22 Jun 2026
Profound Medical Corp. (PROF) Dropped Despite High Potential - Yahoo Finance
Wed, 17 Jun 2026
Profound Medical Corp (PROF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 36 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 47.9 (%) |
| Shares Short | 2,140 (K) |
| Shares Short P.Month | 2,190 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | -206.8 % |
| Operating Margin | -150.3 % |
| Return on Assets (ttm) | -35.5 % |
| Return on Equity (ttm) | -70.6 % |
| Qtrly Rev. Growth | 103.5 % |
| Gross Profit (p.s.) | 0.36 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.97 |
| PEG Ratio | 0 |
| Price to Book value | 4.53 |
| Price to Sales | 14.28 |
| Price to Cash Flow | -6.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|